# US 2015/0031566 A1 · Biotinylated mhc complexes and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031566 A1
- Document ID: US20150031566A1
- Status: Published application
- Kind: A1
- Application number: 14/340,535
- Filed: 2014-07-24
- Published: 2015-01-29
- Earliest claimed: 2006-07-25
- Assignees: ProImmune Limited
- Applicants: Proimmune Limited
- Inventors: Catherine Elizabeth NAPPER; Nikolai Franz Gregor SCHWABE
- Web page: https://patentgrep.com/patent/US20150031566A1

## CPC

- G01N 33/56977: {HLA or MHC typing}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- G01N 33/532: Production of labelled immunochemicals
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/56966: {Animal cells}
- G01N 33/6854: {Immunoglobulins}
- C07K 2319/90: containing a motif for post-translational modification
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- G01N 2440/32: biotinylation
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes.

## Claims

### Claim 1

A chimeric peptide comprising an MHC peptide and a biotinylation peptide which either is a natural biotinylation peptide or has a greater than 70% sequence homology to a natural biotinylation peptide, the biotinylation peptide comprising a minimal sequence from a naturally occurring biotinylation domain that can be biotinylated by a corresponding enzyme.

### Claim 2

The chimeric peptide comprising an MHC peptide and a biotinylation peptide wherein the biotinylation peptide has a minimal sequence required for being biotinylated that is longer than 50 amino acids in length the biotinylation peptide comprising a minimal sequence from a naturally occurring biotinylation domain that can be biotinylated by a corresponding enzyme.

### Claim 3 (depends on 1)

The chimeric peptide of claim 1 wherein the MHC peptide is a Class I MHC peptide or a Class II MHC peptide.

### Claim 4 (depends on 2)

The chimeric peptide of claim 2 wherein the MHC peptide is a Class I MHC or a Class II MHC peptide.

### Claim 5 (depends on 1)

The chimeric peptide of claim 1 wherein the biotinylation peptide is biotinylated.

### Claim 6 (depends on 1)

The chimeric peptide of claim 1 wherein the biotinylation peptide is located in the chimeric protein after the C-terminal end of the MHC peptide.

### Claim 7 (depends on 1)

The chimeric peptide of claim 1 wherein the MHC peptide and the biotinylation peptide are separated by a linker sequence.

### Claim 8 (depends on 1)

The chimeric peptide of claim 1 wherein the biotinylation peptide is selected from the group consisting of the biotinylation domain of BCCP and Proprionibacterium shermanii 1.3S subunit of transcarboxilase.

### Claim 9 (depends on 1)

An MHC peptide complex with the formula (α-β-P), wherein α comprises an α chain of a MHC I or MHC II class molecule, β comprises an β chain of a MHC I or MHC II class molecule, and P is a peptide antigen bound in the binding groove of the MHC molecule, wherein said MHC peptide complex comprises a chimeric peptide of claim 1.

### Claim 10 (depends on 9)

The MHC peptide complex of claim 9, wherein the peptide antigen P bound in the groove is substantially homogeneous.

### Claim 11 (depends on 9)

An Multimeric binding complex having the formula (α-β-P)n, wherein (α-β-P) is the MHC peptide complex of claim 9, and wherein n≧2.

### Claim 12 (depends on 11)

The multimeric binding complex of claim 11 wherein the MHC peptide complexes are biotinylated and the multimeric binding complex is formed by binding the biotinylated MHC peptide complexes to a multivalent entity that binds to biotin with high affinity.

### Claim 13 (depends on 12)

The multimeric binding complex of claim 12 wherein the multivalent entity is an avidin family protein.

### Claim 14 (depends on 11)

The multimeric binding complex of claim 11 comprising a label.

### Claim 15 (depends on 11)

A method of labelling and or detecting mammalian T cells according to the specificity of their antigen receptor, the method comprising
(i) combining a multimeric binding complex according claim 11 and a suspension or biological sample comprising T cells, and
(ii) detecting the presence of specific binding of said complex and at least one of the T cells.

### Claim 16 (depends on 11)

A method of separating mammalian T cells according to the specificity of their antigen receptor, the method comprising
(i) combining a multimeric binding complex according to claim 11 and a suspension or biological sample comprising T cells, and
(ii) separating one or more T cells bound to said complex from unbound cells.

### Claim 17 (depends on 9)

A method of detecting the presence of one or more anti-MHC antibodies in a sample comprising contacting said sample with at least one MHC complex according to any of claim 9 and detecting the binding or absence of binding of the one or more anti-MHC antibodies to either the MHC complex(es).

### Claim 18 (depends on 17)

The method according to claim 17 wherein the antibodies which are detected are IgG, IgM, or IgA.

### Claim 19 (depends on 17)

The method according to claim 17 wherein the peptide antigen P is derived from an antigen that occurs in less than 5% of a population group.

### Claim 20 (depends on 17)

The method according to any of claim 17 wherein the MHC complex(es) is(are) attached to a solid support.

### Claim 21 (depends on 20)

The method according to claim 20 wherein the MHC complex(es) is(are) biotinylated and immobilized to the solid support through binding to an avidin family protein which is itself bound to the solid support.

### Claim 22 (depends on 21)

The method of claim 21 wherein the avidin family protein is streptavidin.

### Claim 23 (depends on 20)

The method according to claim 20 wherein said solid support is a spherical bead.

### Claim 24 (depends on 23)

The method according to claim 23 wherein bead comprises a detectable label.

### Claim 25 (depends on 20)

The method according to claim 20 wherein said solid support is a nitrocellulose strip.

### Claim 26 (depends on 20)

The method according to claim 20 wherein said solid support is an ELISA plate.

### Claim 27 (depends on 17)

The method according to claim 17 wherein the MHC complex(es) is(are) synthesized in a prokaryotic expression system.

### Claim 28 (depends on 17)

The method according to claim 17 wherein the sample is a body fluid sample.

### Claim 29 (depends on 17)

The method according to claim 17 wherein the bound antibody or absence thereof is detected via an immunosorbent assay using an antibody conjugated to a signaling means.

### Claim 30 (depends on 17)

The method according to claim 17 wherein a single solid support is carrying two or more different ones of the MHC complexes or of the multimeric binding complexes at discrete locations on said solid support.

### Claim 31 (depends on 17)

The method according to claim 17 wherein two or more different ones of the MHC complexes or of the multimeric binding complexes are immobilized on a different ones of said solid supports.

### Claim 32 (depends on 17)

A method for determining the suitability of an organ to be transplanted for a transplant recipient, comprising the method of claim 17, wherein the sample is a serum sample of the prospective transplant recipient and the presence of antibodies in the recipient that are reactive to at least one MHC molecule in the organ are detected and at least one MHC allele is determined against which such antibodies are reactive.

### Claim 33 (depends on 17)

A method for determining a rejection reaction against a transplanted organ comprising the method of claim 17, wherein the sample is a serum sample of the transplant recipient by detecting the presence of antibodies in the recipient that are reactive to at least one MHC molecule in the organ are detected and at least one MHC allele is determined against which such antibodies are reactive.

### Claim 34 (depends on 9)

A method of depleting a sample of anti-MHC molecule antibodies comprising at least the steps of contacting said sample with at least one MHC complex of any of claim 9, optionally attached to a solid support, and removing at least the MHC complex from the sample to which at least one anti-MHC antibody contained within the sample has bound.

### Claim 35 (depends on 9)

A kit comprising at least the following components: a) one or more recombinant MHC complexes according to claim 9; b) optionally a solid support, together with means for attachment of the MHC complex(es); and c) a means for detecting anti-MHC-antibodies.

### Claim 36

A method for biotinylating a chimeric peptide, the chimeric peptide comprising an MHC peptide and a biotinylation peptide which either is a natural biotinylation peptide or has a greater than 70% sequence homology to a natural biotinylation peptide wherein the chimeric peptide is incubated in a reaction mixture comprising biotin or a biotin analogue and a biotinylating enzyme, resulting in the biotinylation of the chimeric peptide.

### Claim 37

A method for biotinylating a chimeric peptide, the chimeric peptide comprising an MHC peptide and a biotinylation peptide which is biotinylation peptide is either is a natural biotinylation peptide or has a greater than 70% sequence homology to a natural biotinylation peptide the method comprising (i) constructing a recombinant DNA expression vector that encodes the chimeric peptide, (ii) transforming a recombinant host cell with said vector, and (iii) culturing said host cell in the presence of biotin or a biotin analogue and under conditions such that said fusion protein and a biotinylating enzyme are expressed, resulting in the biotinylation of said chimeric peptide.

### Claim 38

A method for biotinylating a chimeric peptide, the chimeric peptide comprising an MHC peptide and a biotinylation peptide which biotinylation peptide has a minimal sequence required for being biotinylated that is longer than 50 amino acids in length wherein the chimeric peptide is incubated in a reaction mixture comprising biotin or a biotin analogue and a biotinylating enzyme, resulting in the biotinylation of the chimeric peptide.

### Claim 39

A method for biotinylating a chimeric peptide, the chimeric peptide comprising an MHC peptide and a biotinylation peptide which biotinylation peptide has a minimal sequence required for being biotinylated that is longer than 50 amino acids in length the method comprising (i) constructing a recombinant DNA expression vector that encodes the chimeric peptide, (ii) transforming a recombinant host cell with said vector, and (iii) culturing said host cell in the presence of biotin or a biotin analogue and under conditions such that said fusion protein and a biotinylating enzyme are expressed, resulting in the biotinylation of said chimeric peptide.
